natgillin/translations-raw huggingface dataset:
Non-nukleosid-revers-transkriptase-hæmmere (NNRTI'er)
Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Non-nukleoside reverse transkriptasehæmmere (NNRTIer)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Non-radiografisk aksial spondylartrit (nr-aksial SpA)
Non-radiographic axial spondyloarthritis (nr-Axial SpA)
Non-radiografisk aksial spondyloartritis
Non-radiographic axial spondyloarthritits
Non-responder Imputation (NRI) er brugt hos patienter, som udgik af behandlingen, eller hvor data manglede.
Non-responder Imputation (NRI) is used for patients who escaped therapy or had missing data.
Non-respons
Non-response
non-selektive fosfodiesterasehæmmere, som f.eks. pentoxifyllin, selektive fosfodiesterase (PDE 3)-hæmmere, som f.eks. cilostazol eller anagrelide,
non-selective phosphodiesterase inhibitors, such as pentoxifylline, selective phosphodiesterase (PDE 3) inhibitors, such as cilostazol or anagrelide,
non-selektive fosfodiesterasehæmmere, som f.eks.pentoxifyllin, selektive fosfodiesterase (PDE 3)-hæmmere , som f.eks. cilostazol eller anagrelid,
non-selective phosphodiesterase inhibitors, such as pentoxifylline, selective phosphodiesterase (PDE 3) inhibitors, such as cilostazol or anagrelide,
non-selektive phosphodiesterasehæmmere, som f.eks. pentoxifyllin selektive phosphodiesterase 3 (PDE3)-hæmmere, som f.eks. cilostazol eller anagrelid
non-selective phosphodiesterase inhibitors like pentoxifylline, selective phosphodiesterase 3 (PDE3) inhibitors like cilostazol or anagrelide,
Non-steroid-anti- inflammatorisk medicin (NSAID), inklusive selektive cyclooxygenase- 2-hæmmere (COX-2- hæmmere), acetylsalicylsyre (>3 g/dag) og ikke-  selektive NSAID
Non-steroidal anti- inflammatory medicines (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non- selective NSAIDs
Non-steroid-anti- inflammatorisk medicin (NSAID), inklusive selektive cyclooxygenase- 2-hæmmere (COX-2- hæmmere), acetylsalicylsyre (>3 g/dag) og ikke- selektive NSAID
Non-steroidal anti- inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non-  selective NSAIDs
Non-steroid-anti- inflammatorisk medicin (NSAID), inklusive selektive cyclooxygenase- 2-hæmmere (COX-2- hæmmere), acetylsalicylsyre (>3 g/dag) og ikke- selektive NSAID
Non-steroidal anti- inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non- selective NSAIDs
Non-steroid-anti-inflammatorisk medicin (NSAID), inklusive selektive COX-2 hæmmere, acetylsalicylsyre (>3 g/dag) og ikke-selektive NSAID
Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid (>3 g/day), and non-selective NSAIDs
Non-Steroidal Anti- Inflammatory Drugs (NSAIDs) [CYP2C9-substrater]
Non-Steroidal Anti- Inflammatory Drugs (NSAIDs) [CYP2C9 substrates]
Non-steroide anti-inflammatoriske lægemidler (f.eks. ibuprofen og diclofenac) (bruges til behandling af smerter og betændelsestilstande)
Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)
Non-steroide anti-inflammatoriske lægemidler (NSAID)
Non-steroidal anti-inflammatory drugs (NSAIDs)
Non-steroide anti-inflammatoriske lægemidler (NSAID)
Non-steroidal anti-inflammatory medicinal products
Non-steroide anti-inflammatoriske lægemidler (NSAID), såsom ibuprofen, diclofenac eller celecoxib (smertestillende eller betændelseshæmmende lægemidler)
Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac or celecoxib (medicines to relieve pain and inflammation)
Non-steroide anti-inflammatoriske lægemidler (NSAID’ere)
Non-steroidal anti-inflammatory medicinal products
non-steroide anti-inflammatoriske lægemidler,
non-steroidal anti-inflammatory medicinal products,
Non-steroide anti-inflammatoriske stoffer
Nonsteroidal Anti-Inflammatory Drugs
Non-steroide antiinflammatoriske lægemidler
Non-steroidal anti-inflammatory drugs
Non-steroide antiinflammatoriske lægemidler (f.eks. ibuprofen og diclofenac) (bruges til behandling af smerter og betændelsestilstande)
Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)
non-steroide antiinflammatoriske lægemidler,
non-steroidal anti-inflammatory drugs,
non-steroide antiinflammatoriske midler
non-steroidal anti-inflammatory drugs
Non-Steroide Antiinflammatoriske Midler (forkortet NSAID) der ofte tages som smertestillende medicin, såsom ibuprofen og naproxen.
Non-Steroidal Anti-Inflammatory Drugs (abbreviated as NSAIDs) often taken as painkillers such as ibuprofen and naproxen.
Non-steroide antiinflammatoriske midler (NSAIDer) inklusive selektive cyclooxygenase-2 (COX-2)- hæmmere
Non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 (COX-2) inhibitors
Non-steroide antiinflammatoriske midler (NSAIDs): Administration af Efient samtidig med vedvarende behandling med NSAIDs er ikke undersøgt.
Non-steroidal anti-inflammatory drugs (NSAIDs): Concomitant administration with chronic NSAIDs has not been studied.
Non-steroide antiinflammatoriske midler (NSAIDs): Administration af Efient samtidig med vedvarende behandling med NSAIDs givet vedvarende er ikke undersøgt.
Non-steroidal anti-inflammatory drugs (NSAIDs): Concomitant administration with chronic NSAIDs has not been studied.
Non-steroide-anti-inflammatoriske lægemidler (NSAID), inklusive selektive cyclooxygenase-2- hæmmere (COX-2-hæmmere), acetylsalicylsyre og ikke-selektive NSAID: Som for andre stoffer, der påvirker renin-angiotensin-systemet, kan NSAID reducere aliskirens antihypertensive effekt.
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid and non-selective NSAIDs: As with other agents acting on the renin-angiotensin system, NSAIDs may reduce the anti-hypertensive effect of aliskiren.
Non-steroide-anti-inflammatoriske lægemidler (NSAID), inklusive selektive cyclooxygenase-2- hæmmere (COX-2-hæmmere), acetylsalicylsyre og ikke-selektive NSAID: Som for andre stoffer, der virker på renin-angiotensin-systemet, kan NSAID reducere aliskirens antihypertensive effekt.
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid and non-selective NSAIDs: As with other agents acting on the renin-angiotensin system, NSAIDs may reduce the anti-hypertensive effect of aliskiren.
Non-vertebral fraktur2
Non-vertebral fracture2
Non-vertebrale frakturer
Non-vertebral fractures
Nonacog alfa (rekombinant koagulationsfaktor IX) Til intravenøs anvendelse.
Nonacog alfa (recombinant coagulation factor IX) Intravenous use
Nonacog alfa udvindes ikke af humant blod, men fremstilles ved hjælp af en metode, der kaldes "rekombinant DNA-teknologi", dvs. det fremstilles af celler, der har modtaget et gen (DNA), som sætter dem i stand til at danne human koagulationsfaktor IX.
Nonacog alfa is not extracted from human blood but produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA), which makes them able to produce human coagulation factor IX.
Nonacog gamma (rekombinant human koagulationsfaktor IX)
Nonacog gamma (recombinant human coagulation factor IX)
Nonafact 100 IE/ml pulver og solvens til injektionsopløsning Human kogulationsfaktor IX
Nonafact 100 IU/ml Powder and solvent for solution for injection Human coagulation factor IX
Nonafact 100 IE/ml pulver og solvens til injektionsopløsning.
Nonafact 100 IU/ml powder and solvent for solution for injection.
Nonafact 100 IE/ml pulver til injektionsopløsning Human koaguleringsfaktor IX
Nonafact 100 IU/ml powder for solution for injection Human coagulation factor IX
Nonafact 100 IE/ml, human kogulationsfaktor IX
Nonafact 100 IU/ml human coagulation factor IX
Nonafact består af pulver og solvens til injektionsopløsning (glas med 5 eller 10 ml).
Nonafact is presented as a powder and a solvent for solution for injection (vial of 5 ml or 10 ml)
Nonafact har ingen indflydelse på evnen til at føre bil eller betjene maskiner.
Nonafact has no influence on the ability to drive and use machines.
Nonafact indeholder 100 IE/ml (500 IE/5ml eller 1000 IE/10 ml) human koagulationsfaktor IX, når det er blevet rekonstitueret i 5 ml eller 10 ml injektionsvæske.
Nonafact contains 100 IU/ml (500 IU/5ml or 1000 IU/10ml) human coagulation factor IX when reconstituted with 5 ml or 10 ml, respectively, of water for injections.
Nonafact indeholder meget små mængder af det murine, monoklonale antistof, der bruges til oprensningen af faktor IX (< 0,1 ng murint IgG/IE faktor IX).
Nonafact contains trace amounts (< 0.1 ng mouse IgG/IU of factor IX) of the murine monoclonal antibody used in its purification.
Nonafact indeholder:
What Nonafact contains:
Nonafact må aldrig blandes med andre medicinalprodukter.
Nonafact should never be mixed with other medicinal products.
Nonafact skal injiceres i en vene (intravenøs indgivelse).
Nonafact should be injected into a vein (intravenous administration).
Nonafacts sikkerhed og virkning hos born under 6 år er ikke blevet klarlagt.
The safety and efficacy of Nonafact in children less than 6 years of age has not been established.
Nonafacts specifikke aktivitet er mindst 200 IE/mg protein.
The specific activity of Nonafact is at least 200 IU/mg protein.
Nondepolariserende skelet/muskel- relaksanter (fx tubocurarin)
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine)
Nondepolariserende skelet/muskel-relaksanter (fx tubocurarin)
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine)
Noninferioritets-marginen var 15 %.
The non-inferiority margin was 15 %.
Noninferioritetskriterierne var opfyldt, hvis den nedre grænse af 97,5 % konfidensintervallet for forskel i hyppigheden af fuldstændigt respons for intravenøs palonosetron minus intravenøs ondansetron var over -15 %.
Non- inferiority criteria were met if the lower bound of the 97.5% confidence interval for the difference in Complete Response rates of intravenous palonosetron minus intravenous ondansetron was larger than -15%.
Nonkliniske data viser ingen speciel risiko for mennesker vurderet ud fra konventionelle studier af sikkerhedsfarmakologi, toksicitet efter gentagne doser, genotoksicitet eller karcinogenicitet.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential.
Nonlinearitet:
Non-linearity:
Nonsteroide antiinflammatoriske lægemidler (NSAID), inklusive selektive COX-2 hæmmere, acetylsalicylsyre > 3 g/dag) og nonselektive NSAID
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid > 3 g/day), and non-selective NSAIDs
Nonsteroide antiinflammatoriske lægemidler (NSAID’er), herunder salicylsyre, medførte i dyreforsøg et fald i den tubulære udskillelse af methotrexat og forstærkede således dets toksiske virkninger.
In animal experiments non-steroidal anti-inflammatory drugs (NSAIDs) including salicylic acid caused reduction of tubular methotrexate secretion and consequently increased its toxic effects.
Nonsteroide antiinflammatoriske lægemidler: Når angiotensin II-antagonister administreres samtidig med nonsteroide antiinflammatoriske lægemidler (fx selektive COX-2 hæmmere, acetylsalicylsyre (> 3 g/dag) og nonselektive NSAID) kan den antihypertensive virkning svækkes.
Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Nonsteroide antiinflammatoriske midler (NSAID) (en gruppe af smertestillende midler)
Nonsteroidal anti-inflammatory drugs (NSAID) (a type of painkillers)
Nonsteroide antiinflammatoriske midler (NSAID) (en gruppe af smertestillende midler)
Nonsteroidal anti-inflammatory drugs (NSAID) (a type of painkillers).
Nonsteroide antiinflammatoriske midler (NSAID) (en gruppe af smertestillende midler).
Nonsteroidal anti-inflammatory drugs (NSAID) (a type of painkillers).
Nonsteroide antiinflammatoriske stoffer (NSAID’er): I et klinisk forsøg foretaget på raske forsøgspersoner øgede den samtidige administration af clopidogrel og naproxen okkult gastrointestinalt blodtab.
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
Nonsteroide antiinflammatoriske stoffer (NSAID’er): I et klinisk studie foretaget med raske forsøgspersoner øgede den samtidige administration af clopidogrel og naproxen okkult gastrointestinalt blodtab.
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
Nonsteroide antiinflammatoriske stoffer (NSAID’er): I et klinisk studie foretaget på raske forsøgspersoner øgede den samtidige administration af clopidogrel og naproxen okkult gastrointestinalt blodtab.
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
nopret udslæt (papuløst udslæt)
bumpy rash (papular rash)
Noradrenalin og dopamin genoptagelseshæmmer
NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITOR
noradrenalin, dopamin og dobutamin, som bruges til behandling af hjertesygdomme og lavt blodtryk
noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure
Noradrenalin- og dopamin-reuptake-hæmmer
Norepinephrine and dopamine reuptake inhibitor
Norbrook Laboratories Limited Station Works,
Norbrook Laboratories Limited Station Works
Norbuprenorphin AUC ↑105% Norbuprenorphin Cmax ↑61% Norbuprenorphin Cmin ↑101%
Norbuprenorphine AUC ↑105% Norbuprenorphine Cmax ↑61% Norbuprenorphine Cmin ↑101
Norbuprenorphin AUC  79% Norbuprenorphin Cmax  80% Norbuprenorphin Cmin  80%
Norbuprenorphine AUC  79% Norbuprenorphine Cmax  80% Norbuprenorphine Cmin  80
Norbuprenorphin ↑ 33% ↑ 108%
Norbuprenorphine ↑ 33% ↑ 108
Norbuprenorphin:
Buprenorphine/naloxone/Efavirenz
Norbuprenorphin: AUC: ↓ 71%
Norbuprenorphine: AUC: 0 71
Norbuprenorphin: AUC: ↓ 71%
Norbuprenorphine: AUC: ↓ 71
Nordic Group BV, Siriusdreef 22, 2132 WT Hoofddorp, Holland
Nordic Group BV, Siriusdreef 22, 2132 WT Hoofddorp, The Netherlands
Nordic Pharma
Nordic Pharma.
Nordimet 7,5 mg injektionsvæske, opløsning, i fyldt pen Hver fyldt pen indeholder 7,5 mg methotrexat i 0,3 ml
Nordimet 7.5 mg solution for injection in prefilled pen Each pre-filled pen contains 7.5 mg methotrexate in 0.3 mL
Nordimet er beregnet til subkutan anvendelse (se pkt.
Nordimet is for subcutaneous use (see section 6.6.).
Nordimet er et "hybridt lægemiddel".
Nordimet is a ‘hybrid medicine’.
Nordimet er et lægemiddel, der bruges til behandling af en række inflammatoriske sygdomme: aktiv reumatoid artrit hos voksne.
Nordimet is a medicine used to treat a range of inflammatory diseases: active rheumatoid arthritis in adults.
Nordimet er indiceret til behandling af
Nordimet is indicated for the treatment of
Nordimet fyldte penne indeholder en klar gul injektionsvæske, opløsning.
Nordimet pre-filled pens contain a clear, yellow solution for injection.
Nordimet fås som en opløsning i forskellige styrker og skal injiceres under huden én gang om ugen på den samme ugedag.
Nordimet is available as a solution of various strengths and should be injected under the skin once a week on the same day each week.
Nordimet indeholder det aktive stof methotrexat, der virker ved at:
Nordimet contains the active substance methotrexate which works by:
Nordimet methotrexat
Nordimet methotrexate
Nordimet må kun ordineres af læger, der har erfaring med lægemidlets forskellige egenskaber og virkningsmekanisme.
Nordimet should only be prescribed by physicians with experience in the various properties of the medicinal product and its mode of action.
Nordimet skal kun tages én gang om ugen.
Nordimet is administered once a week only.
Norelgestromin (raltegravir 400 mg to gange dagligt)
Ethinyl Estradiol Norelgestromin (raltegravir 400 mg Twice Daily)
Norelgestromin AUC: 1,12 (1,06; 1,17)
Norelgestromin AUC: 1.12 (1.06, 1.17)
Norepinephrinbitartrat
Norepinephrine bitartrate
norethindron
contraceptives and
norethindron
ethindrone
Norethindron (1 mg én gang dagligt)/Rilpivirin
Norethindrone (1 mg once daily)/ Rilpivirine
norethindron 0,035 mg/1 mg én gang dagligt/
0.035 mg once daily/
Norethindron 0,4 mg 1 gang daglig i 15 dage (Nelfinavir 750 mg hver 8. time i 7 dage)
Norethindrone 0.4 mg qd x 15 days (Nelfinavir 750 mg q8h x 7 days)
Norethindron 35 g/1 mg x 1
35 g/1 mg once daily
Norethindron AUC ↑110% (↑68%
Norethindrone AUC ↑110% (↑68
Norethindron AUC ↓ 18 % Nelfinavirkoncentrationer er ikke målt
Norethindrone AUC ↓18
Norethindron Cmax ↑67% (↑42%
Norethindrone Cmax ↑67% (↑42
norethindron Cmax 
ildenafil for the treatment of
norethindron Cmin 1,24 (1,13-1,35) 
norethindrone Cmin 1.24 (1.13-1.35) ↑
Norethindron Cmin ↑262% (↑157%
Norethindrone Cmin ↑262% (↑157
norethindron Cmin ↓ 30 %
For the treatment of
Norethindron: AUC: ↔
Norethindrone: AUC: ↔
Norethisteron 1,0 mg x 1
/ Norethindrone 1.0 mg QD
Norethisteron AUC ↑ 27%
Norethindrone AUC ↑ 27
norethisteron AUC ↓ 4 %
norethindrone AUC ↓4
norethisteron Cmaks. ↓ 17 %
norethindrone Cmax ↓17
Norethisteron Cmax ↔
Norethindrone Cmax ↔
norethisteron vil sandsynligvis
norethindrone is unlikely
norethisteron*
norethindrone
norethisteron/ethinylestradiol
norethindrone/ethinyl
Norge
Magyarország
Norge
Norway.
Norge Meda A/S
Nederland
Norge sanofi-aventis Norge AS Tlf: + 67 10 71 00
Norge sanofi-aventis Norge AS Tlf: + 47 67 10 71 00
Norgestimat (0,180/0,215 mg én
Norgestimate (0.180/0.215 mg
Norgestimat (0,180/0,215 mg én
once daily)
Norgestimat (0,180/0,215 mg én gang daglig)/Ethinylestradiol (0,025 mg én gang daglig)/ Elvitegravir (150 mg én gang daglig)/Cobicistat (150 mg én gang daglig)4
Norgestimate (0.180/0.215 mg once daily)/Ethinylestradiol (0.025 mg once daily)/ Elvitegravir (150 mg once daily)/Cobicistat (150 mg once daily)4
Norgestimat (0,180/0,215 mg én gang daglig)/Ethinylestradiol (0,025 mg én gang daglig)/Elvitegravir (150 mg én gang daglig)/Cobicistat (150 mg én gang daglig)4
Norgestimate (0.180/0.215 mg once daily)/ Ethinylestradiol (0.025 mg once daily)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)4
Norgestimat AUC ↑85% (↑67%
Norgestimate AUC ↑85% (↑67
Norgestimat Cmax ↑68% (↑51%
Norgestimate Cmax ↑68% (↑51
Norgestimat Cmin ↑102% (↑77%
Norgestimate Cmin ↑102% (↑77
norgestimat er ikke undersøgt
norgestimate has not been studied
norgestimat/ethinylestradiol
Emtricitabine:
Norgestimat/ethinylestradiol
Norgestimate/ethinyl estradiol
Norgestimat/Ethinylestradiol
Norgestimate/Ethinyl- estradiol
Norgestimat/Ethinylestradiol/
Norgestimate/Ethinyl oestradiol/
Norgestimat/Ethinylestradiol/ Tenofovirdisoproxilfumarat
Norgestimate/Ethinyl oestradiol/Tenofovir disoproxil fumarate
Norgestimat/ethinylestradiol/tenofovirdisoproxil
IMMUNOSUPPRESSANTS
Norgestimat:
Tacrolimus:
normal
(12/18)
Normal
Unimpaired
Normal (>80) (n=8)
Normal (> 80) (n = 8)
Normal ALAT
Normal ALT
Normal daglig Ribavirin
Usual daily Ribavirin
Normal daglig Ribavirin BioPartners dosis
Usual daily Ribavirin BioPartners dose
Normal daglig Ribavirin Teva Pharma B.V. dosis
Usual daily Ribavirin Teva Pharma B.V. dose
Normal daglig Ribavirin Teva- dosis
Usual daily Ribavirin Teva dose
Normal dosis
Regular dose
Normal dosis
Usual dose
normal fodring
normal feeding
Normal indendørsbelysning er sikker.
Ambient indoor light is safe.
Normal Let Moderat
Normal Mild Moderate
Normal nyrefunktion (≥ 90 ml/min)
Normal renal function (≥ 90ml/min)
Normaldosis
The usual dose
Normaldosis: mellem 0,14 ml (14 mg) og 0,42 ml (42 mg) pr. kg legemsvægt dagligt fordelt på 2 doser dagligt.
General dose: between 0.14 ml (14 mg) and 0.42 ml (42 mg) per kg bodyweight each day, divided in 2 intakes per day.
Normaldosis: mellem 20 mg og 60 mg pr. kg legemsvægt dagligt.
General dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day.
Normale aktiviteter som badning, brusebad, sauna og motion skulle ikke påvirke plasterets virkning.
Normal activities such as having a bath or shower, using a sauna and exercising should not affect how well the patch works.
Normale celler er derimod i stand til at syntetisere L-asparagin og påvirkes i mindre grad af den hurtige tømning ved behandling med enzymet L-asparaginase.
Normal cells, in contrast, are capable of synthesising L-asparagine and are less affected by its rapid withdrawal during treatment with the enzyme L-asparaginase.
Normale celler kan selv lave asparagin, mens nogle af kræftcellerne ikke kan.
Normal cells can make asparagine for themselves, while some cancer cells cannot.
Normale raske mennesker producerer tilstrækkeligt alfa-1- proteinasehæmmer til at kontrollere NE, der produceres af aktiverede neutrofiler, og er således i stand til at forebygge utilsigtet NE-medieret proteolyse af lungevæv.
Normal healthy individuals produce sufficient alpha1-proteinase inhibitor to control the NE produced by activated neutrophils and are thus able to prevent inappropriate proteolysis of lung tissue by NE.
Normale sikkerhedsforanstaltninger for håndtering af radioaktive stoffer skal overholdes.
Normal safety precautions for handling radioactive materials should be observed.
Normalised Ratio) og kan påvirke
inhibitors, an interaction can be
Normalised Ratio) og kan påvirke
unavoidable, this should be done
Normaliseret
Normalized Liver
Normaliseret
Normalized Spleen
Normaliseret ALATd
Normalised ALTd
Normaliseret IGF-1
Normalised IGF-1
Normalisering (≤4 x 109/l)
Normalisation (≤4x109/l)
Normalisering af
Normalization of
Normalisering af ALAT- niveauer opstod hos 31 % (14/45) af de patienter, der fik kombinationsbehandling, versus hos 6 % (3/47) af de patienter, der fik lamivudin-monoterapi.
Normalisation of ALT levels occurred in 31 % (14/45) of patients receiving combined therapy versus 6 % (3/47) receiving lamivudine alone.
Normalisering af ALAT- niveauer opstod hos 31 % (14/45) af de patienter, der modtog kombinationsbehandling versus hos 6 % (3/47) af de patienter, der fik lamivudin monoterapi.
Normalisation of ALT levels occurred in 31 % (14/45) of patients receiving combined therapy versus 6 % (3/47) receiving lamivudine alone.
Normalisering af ALATa
Normalisation of ALTa
Normalisering af ASATb
Normalisation of ASTb
Normalisering af trombocyttal
Platelet count normalization
normalisering n/N (%)
normalisation n/N (%)
normalisering, n (%)
response, n (%) (95
Normalmente la primera y más frecuente manifestación de supresión hematológica es la neutropenia.
Neutropenia is generally the first and most common manifestation of haematological suppression.
Normalt behandles alvorlige blødninger på hospitalet, og du kan injicere den første NovoSeven dosis på vejen dertil
Usually severe bleeds are treated at the hospital and you can give yourself the first NovoSeven dose on the way there.
Normalt behandles alvorlige blødninger på hospitalet, og du kan injicere den første NovoSeven-dosis på vejen dertil
Usually severe bleeds are treated at the hospital and you can give yourself the first NovoSeven dose on the way there.
Normalt bør dette lægemiddel ikke gives mere end én gang til samme patient.
It should not usually be used on more than one occasion in any one patient.
Normalt bør du være i stand til at mærke når blodsukkeret falder for meget, så du kan tage de rette forholdsregler
You normally should be able to recognise when your blood sugar is falling too much so that you can take the right actions.
Normalt er dosisjustering ikke nødvendig, men leukocytternes cystinniveau bør følges.
Dose adjustment is not normally required; however, WBC cystine levels should be monitored.